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Abstract
Bacterial growth environment strongly influences the efficacy of antibiotic treatment, with
slow growth often being associated with decreased susceptibility. Yet in many cases the
connection between antibiotic susceptibility and pathogen physiology remains unclear. We
show that for ribosome-targeting antibiotics acting on Escherichia coli, a complex interplay
exists between physiology and antibiotic action; for some antibiotics within this class faster
growth indeed increases susceptibility, but for other antibiotics the opposite is true. Remark-
ably, these observations can be explained by a simple mathematical model that combines
drug transport and binding with physiological constraints. Our model reveals that growth-
dependent susceptibility is controlled by a single parameter characterizing the ‘reversibility’
of antibiotic transport and binding. This parameter provides a spectrum-classification of
antibiotic growth-dependent efficacy that appears to correspond at its extremes to existing
binary classification schemes. In these limits the model predicts universal, parameter-free
limiting forms for growth inhibition curves. The model also leads to non-trivial predic-
tions for the drug susceptibility of a translation-mutant strain of E. coli, which we verify
experimentally. Drug action and bacterial metabolism are mechanistically complex; never-
theless this study illustrates how coarse-grained models can be used to integrate pathogen
physiology into drug design and treatment strategies.
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Introduction
Quantitative predictions for the inhibition of bacterial growth by antibiotics are essential
for the design of treatment strategies [1] and for controlling the evolution of antibiotic
resistance [2–5]. The efficacy of antibiotic treatment can be strongly affected by changes
in pathogen physiology, such as biofilm formation [6], switching to persister states [7], and
responses to metabolic stimuli [8]; with slow bacterial growth often being associated with
decreased antibiotic susceptibility [9–11]. Yet, despite its importance, in most cases the
connection between bacterial physiology and antibiotic susceptibility remains unclear. Here
we show that for ribosome-targeting antibiotics in Escherichia coli a strong correlation
exists between physiology, controlled by the nutrient quality of the growth environment,
and antibiotic susceptibility.
Ribosome-targeting antibiotics constitute a major class of antibacterial drugs in current
clinical use. Within this class, different drugs bind to different ribosomal target sites, inhibit
different aspects of ribosome function and may bind to their target with varying degrees of
reversibility [12, 13]. We investigate four different ribosome-targeting antibiotics, two of
which bind almost irreversibly, and two of which bind reversibly. Specifically, streptomycin
and kanamycin are aminoglycosides which bind irreversibly to the 30S ribosomal complex,
inhibiting initiation and inducing mistranslation [14]. We also study the reversibly-binding
drugs tetracycline, which targets the 30S complex, inhibiting the binding of aminoacyl tRNA
[15], and chloramphenicol, which targets the 50S ribosomal complex, preventing peptide
bond formation [16, 17]. We find that the efficacies of these antibiotics exhibit qualitatively
different responses to changes in the bacterial growth environment.
It has long been known that the ribosome content of a bacterial cell correlates closely with
its growth rate under conditions of exponential growth [18, 19]. Recently, it has been shown
that this phenomenon can be understood as a growth-rate dependent partitioning of the
cell’s translational resources between production of new ribosomes and production of other
proteins [20, 21]. This partitioning can be described by a set of empirically-determined
constraints, analogous to the rules that govern the behaviour of electric circuits [20, 22].
Empirical growth constraints provide a physiological chassis into which mechanistic models
for the expression of synthetic gene circuits, or endogenous genes, have been integrated
[23, 24].
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The fact that the cell’s ribosome content is growth-rate dependent suggests that the
efficacy of ribosome-targeting antibiotics should likewise exhibit growth-rate dependence.
We demonstrate that bacterial susceptibility to ribosome-targeting antibiotics does indeed
depend strongly on the nutrient environment as characterized by the bacterial growth rate
prior to antibiotic treatment. Surprisingly, although the four antibiotics used in our study
share the same target, we observe contrasting forms for the efficacy-growth rate relations of
different antibiotics.
These intriguing results can be explained by a simple mathematical model for antibi-
otic transport and ribosome binding which incorporates the empirical growth constraints;
growth inhibition relations which are predicted by the model are in quantitative agreement
with our data for both wild type and mutant strains of E. coli. A single dimensionless param-
eter, which characterizes the reversibility of transport and binding relative to the drug-free
growth rate, emerges from our analysis, providing a simple way to predict how changes in
antibiotic chemistry, pathogen genetics or physiological state will affect drug response. This
‘reversibility parameter’ provides a robust classification of ribosome-targeting antibiotics
according to their growth-rate efficacy relations, with implications for clinical practice and
for the evolution of antibiotic resistance. In particular, reversible antibiotics are predicted
to work better on fast-growing infections, whereas irreversible antibiotics are more effective
for slow-growing pathogens. From a wider perspective, the approach taken here, in which
empirical physiological constraints are coupled with models for molecular mode-of-action,
could reveal similar surprising growth-rate efficacy relations in other classes of antibiotics.
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FIG. 1: Antibiotic susceptibility depends on nutrient quality for four ribosome-targeting antibiotics:
irreversibly-binding antibiotics streptomycin (A & B) and kanamycin (C & D), and reversibly-
binding antibiotics tetracycline (E & F) and chloramphenicol (G & H). The left panels show
the growth rate λ of E. coli MG1655 relative to the drug-free growth rate λ0, as a function of
the antibiotic concentration. Growth inhibition data are shown for media with glycerol as the
carbon source. The arrows indicate increasing drug-free growth rate λ0. The right panels show the
half-inhibition concentration IC50 as a function of the drug-free growth rate λ0. Carbon sources
are denoted by symbol: glucose (circles), glycerol (squares), and error bars denote the standard
deviation among repeated measurements (Tables S2 and S3). Media are variants of Neidhardt’s
MOPS buffered medium [25]; see Methods for details.5
Results
Antibiotic efficacy depends on growth rate
To investigate the link between bacterial growth environment and susceptibility to ribosome-
targeting antibiotics, we measured growth inhibition curves (exponential growth rate as a
function of antibiotic concentration) for E. coli cells on media of increasing nutrient quality.
As the nutrient quality increases, so too does the ‘drug-free growth rate’ λ0, i.e. the expo-
nential growth rate in the absence of antibiotic (Fig. 1, colorbar and Table S1). For the four
ribosome-targeting antibiotics streptomycin, kanamycin, tetracycline and chloramphenicol,
the growth inhibition curves indeed exhibit a strong dependence on the drug-free growth
rate λ0 (Fig. 1, left panels and Table S2).
Bacterial susceptibility to antibiotic can be quantified by the IC50: the antibiotic
concentration needed to halve the bacterial growth rate. Plotting the IC50 as a function
of the drug-free growth rate λ0, we observe contrasting trends between antibiotics (Fig. 1,
right panels and Table S3). For the irreversibly-binding antibiotics streptomycin and
kanamycin, the IC50 increases with nutrient quality, i.e. faster-growing cells are less
susceptible to antibiotic. In contrast, for the reversibly-binding antibiotics tetracycline
and chloramphenicol, the IC50 predominantly decreases as nutrient quality increases, i.e.
faster-growing cells are more susceptible to antibiotic treatment. Data sets for glycerol and
glucose-based media show distinct trends in IC50 with drug-free growth rate. The shapes of
the growth inhibition curves also differ markedly between the two groups of antibiotics: we
observe threshold-like inhibition, i.e. a sharp decrease in growth rate, for streptomycin and
kanamycin (Fig. 1A & C), and more gradual inhibition for tetracycline and chloramphenicol
(Fig. 1E & G). Despite having similar targets, these antibiotics appear to respond to
changes in cell physiology in very different ways.
Mathematical model
Our experimental data can be explained by a simple mathematical model. In our model,
antibiotic molecules enter a bacterial cell and bind to ribosomes, while at the same time,
new ribosomes are synthesized and the cell contents are diluted by growth. Our model is
placed within a physiological context via the empirical growth constraints [20, 22].
In the model, the state of the cell is described by the intracellular concentration of an-
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FIG. 2: Schematic view of the model and its dynamics. A. The model is focused on three
state variables: the intracellular concentration of antibiotic a, the concentration ru of ribosomes
unbound by antibiotic and the concentration rb of antibiotic-bound ribosomes. Two mechanisms
drive the dynamics: 1. Transport across the cell membrane and 2. Binding of ribosomes and
antibiotic. B. Constraints arising from empirical relations between ribosome content and growth
rate. Scott et al. [20] measured total ribosome content as a function of growth rate. When
growth rate is varied by nutrient composition, in the absence of antibiotics, ribosome content ru
correlates positively with growth rate λ, increasing linearly from a minimum concentration of
inactive ribosomes rmin (solid line). When growth rate is decreased by imposing translational
inhibition, total ribosome content rtot = ru + rb increases, reaching a maximum rmax as growth
rate decreases to zero (dashed lines). Note that Scott et al. measured ribosome mass fraction;
here we translate these to concentrations (see Supplementary Information, Fig. S1).
tibiotic a, the concentration ru of ribosomes unbound by antibiotic and the concentration rb
of antibiotic-bound ribosomes (Fig. 2A). Two mechanisms drive the dynamics: 1. transport
of extracellular antibiotic aex into the cell at rate J(aex, a) = Pinaex − Pouta, where Pin and
Pout quantify the permeability of the cell membrane in the inward and outward directions;
and 2. binding of ribosomes and antibiotic f(ru, rb, a) = −kon a (ru − rmin) + koff rb, with
binding and unbinding rate constants kon and koff , respectively, and equilibrium dissociation
constant KD = koff/kon (the inactive fraction rmin is assumed not to bind the antibiotic).
In exponential growth, cell contents are diluted at rate λ, new ribosomes are synthesized at
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rate s(λ), and the dynamics of the system are governed by the following equations:
da
dt
= −λ a+ f(ru, rb, a) + J(aex, a), (1)
dru
dt
= −λ ru + f(ru, rb, a) + s(λ), (2)
drb
dt
= −λ rb − f(ru, rb, a). (3)
This model is coupled to cell physiology via the empirical relations of Scott et al [20],
which link the growth rate λ and ribosome synthesis rate s(λ) to the ribosome concentration;
these act as constraints on the dynamical equations 1-3. The first empirical growth constraint
states that the unbound ribosome content ru and the growth rate λ are linearly proportional:
ru = λ/κt + rmin. (4)
Here, rmin = 19.3µM is the minimal unbound ribosome content needed for growth and the
translational capacity κt = 0.06µM
−1h−1 is related to the maximum peptide elongation
rate [26]. This relation emerges from experiments in which the growth rate is varied by
changing the nutrient source in the absence of antibiotic (green arrow in Fig. 2B; see also
the Supplementary Information). The second empirical growth constraint describes how the
ribosome content is upregulated in response to translational inhibition. Upon decreasing
the growth rate by translational inhibition (for a fixed nutrient source), the total ribosome
content rtot increases linearly, reaching a fixed maximal value rmax = 65.8µM as λ→ 0 [20]
(red arrow in Fig. 2B; see also the Supplementary Information). This can be expressed
mathematically as
rtot = ru + rb = rmax − λ∆r
(
1
λ0
− 1
κt∆r
)
, (5)
where ∆r = rmax − rmin = 46.5µM is the dynamic range of the ribosome concentration.
The implication of the second empirical growth constraint, Eq. 5, is that cells that are
initially growing more slowly have a greater capacity to upregulate their ribosome content
upon antibiotic challenge (steeper slope of the dashed line in Fig. 2B) than those that are
initially growing fast; i.e., slowly growing cells can increase their ribosome content with
little resulting change in their growth rate. Adding together Eqs 2 and 3 at steady state
(dru/dt = drb/dt = 0) shows that the ribosome synthesis rate s(λ) is the product of growth
rate and total ribosome content,
s(λ) = λrtot = λ
[
rmax − λ∆r
(
1
λ0
− 1
κt∆r
)]
. (6)
8
Quantitative results for growth-inhibition curves
Solving the model equations 1-3 at steady state, together with the physiological constraints,
Eqs 4 and 5, produces a universal equation that links the steady-state relative growth rate
λ/λ0 to the extracellular antibiotic concentration aex (see Supplementary Information; here
we have assumed that the antibiotic binding rate kon typically exceeds the translational
capacity κt by several orders of magnitude, kon  κt). This equation is
0 =
(
λ
λ0
)3
−
(
λ
λ0
)2
+
(
λ
λ0
)[
1
4
(
λ∗0
λ0
)2
+
aex
2 IC∗50
(
λ∗0
λ0
)]
− 1
4
(
λ∗0
λ0
)2
. (7)
Remarkably, Eq. 7 states that the growth-dependent antibiotic susceptibility is controlled
by only two parameter combinations, defined as follows: a rate λ∗0, which characterizes the
reversibility of antibiotic transport and binding:
λ∗0 = 2
√
PoutκtKD, (8)
and a concentration scale
IC∗50 =
∆rλ∗0
2Pin
. (9)
In the model, λ∗0 is used to normalize the drug-free growth rate λ0 and IC
∗
50 is used to normal-
ize the extracellular antibiotic concentration aex, and later the half-inhibition concentration
IC50.
Predictions for growth inhibition curves can be obtained by solving Eq. 7; the shapes of
these curves depend only on the value of λ∗0. For small values of λ
∗
0 (the irreversible limit),
the model predicts a discontinuous drop in growth rate at the IC50, as we see in our data
for streptomycin and kanamycin (Fig. 1 and Fig. 3). Interestingly, in this case the model
predicts a bistable dependence of growth rate on antibiotic concentration at the level of
individual cells (Fig. S2). For larger values of λ∗0 (the reversible limit), the model instead
predicts a smooth decrease in growth rate over a wide range of antibiotic concentrations, as
we observe for tetracycline and chloramphenicol (Fig. S2, Fig. 1 and Fig. 3).
Fitting the model to the data via the parameters λ∗0 and IC
∗
50 yields excellent agreement
for tetracycline and chloramphenicol, and reasonable agreement for streptomycin and
kanamycin (Fig. 3). In all cases, the fitted parameters λ∗0 and IC
∗
50 differ between the
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two carbon sources (Table S3), suggesting carbon-source effects on transporter-mediated
influx and outflux (Pin and Pout, respectively) [8]. The fitted parameters are in good
agreement with biochemical parameter values available from literature data (Table S4) and
are consistent with the fact that aminoglycosides are believed to bind and be transported
irreversibly (small λ∗0) [14], whereas for tetracycline and chloramphenicol both transport
and binding processes are reversible (λ∗0) [17, 27]. For kanamycin the agreement is less
accurate than for streptomycin; this deviation may be ascribed to the presence of an
additional binding site on the ribosome with comparable affinity [28, 29], a property not
considered in our model. Nonetheless, our model correctly predicts the sigmoidal form of
kanamycin’s growth-inhibition curve and the decreasing susceptibility with growth rate.
Universal growth-dependent antibiotic susceptibility curve
One of the major insights provided by the model is a simple explanation for the contrasting
trends in growth-dependent susceptibility for different antibiotics which we observe in our
experiments. Substituting aex = IC50 and λ = λ0/2 into Eq. 7, we find that, for all antibi-
otics, the growth-rate dependence of the half-inhibition concentration IC50 is predicted to
fall onto a universal ‘growth-dependent susceptibility’ curve
IC50
IC∗50
=
1
2
[
λ0
λ∗0
+
λ∗0
λ0
]
. (10)
Eq. 10 is derived in the Supplementary Information and holds for kon  κt. Rescaling our
data using the values of λ∗0 and IC
∗
50 obtained from the growth-inhibition curve fits of Fig. 3
(and the equivalent fit for the glucose-based media; Table S3), Figure 4 shows that our data
indeed collapse on to this universal curve.
If the drug-free growth rate λ0 exceeds the critical reversibility rate λ
∗
0, the model (Eq.
10) predicts that the IC50 will increase with λ0; i.e. fast-growing cells will be less susceptible,
as we observe for streptomycin and kanamycin. In contrast, if the drug-free growth rate λ0
is less than the critical reversibility rate λ∗0, Eq. 10 predicts that the IC50 will decrease as λ0
increases; i.e. fast-growing cells will be more susceptible, as we observe for tetracycline and
chloramphenicol. The critical parameter IC∗50 provides a growth-rate independent scale for
the extracellular antibiotic concentration; we find that an antibiotic concentration aex > IC
∗
50
is required for effective growth inhibition, regardless of the drug-free growth rate.
The universal growth-dependent susceptibility curve, Eq. 10 (Fig. 4), suggests that the
10
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FIG. 3: Model fits to growth inhibition curve data. The parameters λ∗0 and IC
∗
50 are obtained
by numerical fitting of the solution of the cubic equation, Eq. 7, to our experimental growth
inhibition curves. Data sets for different drug-free growth rates (i.e. the different curves in
each panel) were fitted simultaneously with the same values of λ∗0 and IC
∗
50, but separate fits
were obtained for glycerol-based and glucose-based media. Here we show the resulting fits for
glycerol-based media (symbols as in Fig. 1.). The parameters obtained by this procedure are:
Streptomycin, glycerol: λ∗0 = 0.31h−1, IC
∗
50 = 0.19µg/ml, streptomycin, glucose: λ
∗
0 = 0.57h
−1,
IC∗50 = 0.36µg/ml, kanamycin, glycerol: λ∗0 = 0.17h−1, IC
∗
50 = 0.05µg/ml, kanamycin, glucose:
λ∗0 = 0.47h−1, IC
∗
50 = 0.26µg/ml, tetracycline, glycerol: λ
∗
0 = 5.2h
−1, IC∗50 = 0.23µM, tetracycline,
glucose: λ∗0 = 6.3h−1, IC
∗
50 = 0.36µM, chloramphenicol, glycerol: λ
∗
0 = 1.8h
−1, IC∗50 = 2.5µM,
chloramphenicol, glucose: λ∗0 = 1.5h−1, IC
∗
50 = 4.1µM. These values of λ
∗
0 and IC
∗
50 are compared
to literature data in Table S4. Similar results are obtained if we instead fit our data directly to the
predicted universal relation for IC50(λ0) (Eq. 10); see Supplementary Information and Fig. S3.
ratio (λ0/λ
∗
0) of the drug-free growth rate λ0 to the ‘reversibility’ rate λ
∗
0 =
√
κtPoutkoff
provides a natural spectrum classification of antibiotic action, integrating growth environ-
ment (through λ0) with antibiotic chemistry and pathogen genetics (through the molecular
parameters which are combined in λ∗0). Drug-pathogen interactions characterized by small
values of λ∗0 are predicted to behave like our irreversible antibiotics (streptomycin and
11
0.1 1 10
λ0/λ0*
1
10
IC
50
/C
*
Streptomycin
Kanamycin
Tetracycline
Chloramphenicol
FIG. 4: Universal growth-dependent susceptibility curve. Data from the right panels of Fig. 1
are rescaled by λ∗0 and IC∗50, obtained by fitting our growth inhibition data (Fig. 3). The black
line shows the model prediction for the universal curve, Eq. 10.
kanamycin); showing decreased efficacy under rich nutrient conditions. Drug-pathogen
interactions characterized by large values of λ∗0 are expected to behave like the reversible
antibiotics in our study (chloramphenicol and tetracycline); showing increased efficacy
under rich nutrient conditions. Drugs with values of λ∗0 close to the drug-free growth rate
λ0 achievable in experiments may show non-monotonically varying susceptibility as nutrient
quality is varied; our data suggest this may in fact be the case for chloramphenicol (Fig. 1H),
in agreement with literature-value estimates for λ∗0 (Table S4). Low outward permeability
has been implicated in growth bistability and masking of resistance mutations [30, 31]
(see in particular the discussion of Ref.[30] in the Supplementary Text); we propose
that irreversibility in binding and transport is a major determinant of growth-dependent
antibiotic susceptibility.
Simple predictions in the reversible and irreversible limits
In the limiting cases of very large or very small λ∗0, i.e. the limits in which antibiotic trans-
port and binding is either fully reversible or fully irreversible, the model leads to simple pre-
dictions for the growth inhibition curve and growth-rate dependence of the half-inhibition
concentration IC50. For small λ
∗
0 (the irreversible limit), a qualitatively different, discontin-
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uous, form for the growth inhibition curve is predicted by Eq. 7:
λ
λ0
=
1
2
[
1 +
√
1− aex
IC50
]
, (11)
for aex < IC50 and zero for aex > IC50. In this case, the IC50 = IC
∗
50λ0/(2λ
∗
0) = λ0∆r/(4Pin)
increases linearly with the drug-free growth rate λ0 (see Supplementary Information). For
large λ∗0 (the reversible limit), the growth inhibition curve obtained from solving Eq. 7 is
given by the smoothly-varying, Langmuir form:
λ
λ0
=
1
1 + aex/IC50
, (12)
where aex is the extracellular antibiotic concentration and the IC50 = IC
∗
50λ
∗
0/(2λ0) =
KD × (Pout/Pin) × (κt∆r/λ0) is inversely proportional to the drug-free growth rate λ0 (see
Supplementary Information).
Scaling all our growth inhibition curves by the drug-free growth rate λ0 and the
half-inhibition concentration IC50 we find that our combined data sets for the reversible
and irreversible drugs collapse onto these two qualitatively distinct, parameter-free curves,
as predicted by the model (Fig. 5) – although, as expected, the quantitative agreement
with the limiting-case theoretical prediction is not quite as good as with the full solution of
the cubic equation (Fig. 3).
Testing the model predictions for a translation mutant strain of E. coli
In our model, the key parameters λ∗0 and IC
∗
50 (defined in Eqs 8 and 9) depend on the
translational capacity κt. To test the predictions of the model, we used a strain of E.
coli MG1655 in which the ribosome is mutated such that the peptide elongation rate is
decreased [32], with a corresponding decrease in the translational capacity [20]. Measuring
the RNA-to-protein ratio, which is proportional to the ribosome concentration ([20]; see
Supplementary Material) as a function of growth rate in the absence of antibiotics and
using Eq. 4, we found that the translational capacity κt for the mutant is decreased by a
factor of 0.65 relative to that of the wildtype, κMUTt = 0.65κ
WT
t (Fig. 6A and Table S5).
For the reversible antibiotic tetracycline, we expect that the IC50 is well-approximated by
the limiting form, IC50 = (κt/λ0)×KD × (Pout/Pin)×∆r; thus the ratio of susceptibilities
between the wildtype and mutant strains ICWT50 /IC
MUT
50 should be proportional to the ratio
of drug-free growth rates λMUT0 /λ
WT
0 , with proportionality constant κ
WT
t /κ
MUT
t = 1/0.65.
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FIG. 5: Growth inhibition curves for our reversibly- and irreversibly-binding drugs collapse
onto two qualitatively different limiting forms as predicted by the model. A: Data for the
irreversible antibiotics streptomycin (closed symbols) and kanamycin (open symbols) collapse onto
λ/λ0 = (1/2)[1 +
√
1− aex/IC50] (black line). B: Data for the reversible antibiotics tetracycline
(closed symbols) and chloramphenicol (open symbols) collapse onto λ/λ0 = 1/[1+aex/IC50] (black
line).
Indeed, when rescaled relative to the IC50 of the mutant in minimal media, our results for
the wild-type IC50 values, measured for our 6 nutrient conditions, do fall on the predicted
straight line with gradient 1/0.65 irrespective of carbon source (Fig. 6B; for raw data see
Table S6).
We also investigated the response of the translational mutant to the irreversibly-binding
drug kanamycin. Here, the situation is more complex because the mutant confers partial
resistance to kanamycin (and full resistance to streptomycin), meaning that other molecular
parameters are likely to be altered along with κt. Nevertheless, growth inhibition curves
for the mutant in the presence of kanamycin are well-fitted by our model (Fig. S4).
Mechanistic link between reversibility timescale and growth-dependent suscep-
tibility
Why does our model behave qualitatively differently in the limits where antibiotic transport
and binding are irreversible (small λ∗0) and where they are reversible (large λ
∗
0)? In the model,
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FIG. 6: The translation mutant shows growth-dependent susceptibility to tetracycline in quan-
titative agreement with the model predictions. A: The mutant shows a reduced translational
capacity compared to the wildtype strain. Translational capacity is given as the inverse slope
of a plot of the RNA/protein ratio versus drug-free growth rate λ0 (in h
−1) [20]. The data
for the mutant are from this study (dashed line); wildtype data are taken from Scott et al.
[20] (solid line). The ratio of slopes (WT/MUT) gives the ratio of translational capacity
κMUTt /κ
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t = 0.65 (Table S5). The colored symbols indicate different growth media, as in
Fig. 1. B: Growth-dependent susceptibility to tetracycline for the translation mutant. The
model predicts that for a reversible drug such as tetracycline, IC50 =IC
∗
50λ
∗
0/(2λ0), so that
ICWT50 /IC
MUT
50 = (κ
WT
t /κ
MUT
t )× (λMUT0 /λWT0 ) = (1/0.65)× (λMUT0 /λWT0 ) (since both λ∗0 and IC∗50
are proportional to
√
κt). The symbols show IC
WT
50 measured on all 6 growth media, divided by
the ICMUT,MIN50 measured on glucose minimal or glycerol minimal medium as appropriate, and the
drug-free growth rate of the wildtype λWT0 similarly rescaled with respect to the drug-free growth
rate of the mutant in the corresponding minimal medium λMUT,MIN0 . The data collapse onto a
straight line with gradient (1/0.65), as indicated by the solid black line. It is important to note that
the solid line is not a line-of-best-fit, but rather comes from taking the ratio of the slopes in panel A.
nutrient quality has two opposing influences on the cell’s ribosome content: it increases the
size of the ribosome pool (solid line in Fig. 2B) but it also reduces the cell’s capacity to
increase this pool in response to antibiotic challenge (gradient of the dashed lines in Fig. 2B).
In other words, fast-growing cells have a ribosome pool which is already close to maximal
and have little capacity to increase in response to antibiotic, while slow-growing cells have
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FIG. 7: Shift in the network topology in the irreversible and reversible limits. A. In the limit
that either transport or binding are irreversible (as is the case for streptomycin and kanamycin),
the system exhibits a ‘toggle-switch’ topology, leading to a steep inhibition curve (Eq. 11).
B. In the limit of fully-equilibrated transport and binding (as is the case for tetracycline and
chloramphenicol), the model predicts more gradual inhibition (Eq. 12).
a small ribosome pool that can be increased by a large factor in response to antibiotic.
In the limit that either transport or binding are irreversible (small λ∗0), antibiotic
molecules that enter the cell are neutralized by binding to free ribosomes, such that the
intracellular antibiotic concentration remains low. The model exhibits a ‘toggle-switch’
topology (Fig. 7A), in which free ribosomes “soak up” antibiotic, while antibiotic inacti-
vates free ribosomes. If the extracellular antibiotic concentration aex is below a threshold
determined by the initial (unbound) ribosome concentration, the cell generates ribosomes
fast enough to neutralize all the antibiotic that enters the cell. If, however, aex exceeds the
threshold, the cell’s rate of ribosome generation cannot compete with the antibiotic influx
and the system flips to a different steady-state with no free ribosomes and correspondingly
no growth. Thus in the irreversible limit the fate of a cell is determined by a “molecular
race” between antibiotic influx and ribosome production, in which the absolute number of
ribosomes is decisive. Fast-growing cells (on rich nutrient) have a larger ribosome pool and
correspondingly higher ribosome synthesis rate, so that they are able to tolerate a higher
rate of antibiotic influx than slow-growing cells.
In contrast, in the limit of fully-reversible transport and binding (large λ∗0), the free
and bound ribosome pools are in equilibrium (Fig. 7B), and the intra- and extra-cellular
antibiotic pools are also in equilibrium. Increasing the antibiotic concentration shifts
the equilibrium between free and bound ribosome pools; the cell responds by increasing
the total ribosome pool (dashed line in Fig. 2B). This leads to a smoothly-varying,
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Langmuir-like dependence of the relative growth rate λ/λ0 on the extracellular antibiotic
concentration aex. Because λ/λ0 is determined by the relative sizes of the ribosome pool
in the presence and absence of antibiotic, the half-inhibition concentration depends on the
slope of the dashed line in Fig. 2B. Slow-growing cells have more capacity to increase their
ribosome pool (steeper slope of the dashed line; Fig. 2B), and as a consequence they are
less susceptible to antibiotic than fast-growing cells.
Discussion
Taken together, our results show that bacterial susceptibility to ribosome-targeting antibi-
otics exhibits strong growth-rate dependence, but that the nature of this dependence differs
qualitatively between antibiotics (Fig. 1). For irreversibly-binding antibiotics (streptomycin
and kanamycin), slower growing cells are more susceptible; whereas for reversibly-binding
antibiotics (tetracycline and chloramphenicol), faster growing cells are more susceptible.
This behaviour can be understood by a simple mechanistic model which shows that these
contrasting effects of nutrient environment on susceptibility for different antibiotics can be
explained in terms of a single parameter, the critical reversibility rate λ∗0 (Eq. 8), which
characterizes the outward permeability and binding affinity of the drug.
Our model predicts a parameter-free relation for the growth-dependent susceptibility
(Eq. 10), i.e. how the IC50 depends upon the drug-free growth rate λ0 relative to the
critical reversibility rate λ∗0. This relation is in very good agreement with the experimental
data (Fig. 4). If the pathogen drug-free growth rate λ0 is larger than λ
∗
0 the IC50 increases
with drug-free growth rate (as it does for our irreversible antibiotics streptomycin and
kanamycin), so that slow-growing cells are more susceptible. In contrast, if the pathogen
drug-free growth rate is smaller than λ∗0 (as for our reversible antibiotics tetracycline and
chloramphenicol) the IC50 decreases with drug-free growth rate, so that fast-growing cells
are more susceptible. Our model also predicts very different shapes for the growth-inhibition
curves in these two cases; if λ0 > λ
∗
0 (as for our irreversible drugs), the growth-inhibition
curves show a sharp drop around the IC50, while if λ0 < λ
∗
0 (as for our reversible drugs),
we expect smoothly varying growth-inhibition curves. Moreover, in the reversible and
irreversible limits of large and small λ∗0, our model leads to parameter-free predictions for
both growth-dependent susceptibility (Eq. 10) and growth inhibition curves (Eqs. 11 and
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12), which are confirmed by a collapse of the data points on the predicted re-scaled curves
(Fig. 5). Finally, the insight provided by our analysis allows us to make sucessful predictions
for how antibiotic susceptibility is modified by a mutation affecting translation rate (Fig. 6).
Significance of the critical reversibility rate λ∗0
A major insight arising from this study is the importance of the critical reversibility rate
λ∗0 in determining susceptibility to antibiotic treatment. For a given ribosome-targeting
antibiotic and pathogenic strain, λ∗0 can be inferred from known biochemical parameters
(via Eq. 8) in cases where these are known, or, alternatively, estimated by measuring
inhibition curves over a range of drug-free growth rates (a task well-suited to automation
[33]). This critical reversibility rate provides a spectrum classification of ribosome-targeting
antibiotics according to their physiological effects, which, interestingly, appears to correlate
at its extremes with existing binary classification schemes, at least for the antibiotics used
in this study. In particular, the irreversible antibiotics streptomycin and kanamycin are
classified as bactericidal, whereas the reversible antibiotics tetracycline and chloramphenicol
are classified as bacteriostatic. This is consistent with the fact that our model predicts
a rapidly-vanishing growth rate beyond the IC50 for irreversible antibiotics (i.e. those
with small values of λ∗0). Our classification on the basis of λ
∗
0 also correlates with the fact
that streptomycin and kanamycin are known to transiently induce expression of proteins
associated with heat-shock in E. coli, whereas tetracycline and chloramphenicol induce
expression of proteins associated with cold-shock [34]. It remains to be seen whether these
responses are triggered directly by the antibiotic or are associated more generally with
physiological changes occurring in the organism.
Coupling of cell physiology and antibiotic mode-of-action
In a wider context, bacterial growth rate is an important factor controlling gene expression
and regulation [21, 23], imposing strong constraints on the allocation of cellular resources.
These constraints lead to intrinsic growth-rate dependence in the macromolecular composi-
tion of the cell [20, 35]. Consequently, it is to be expected (and in some cases it is known [9–
11, 36]) that antibiotic susceptibility likewise exhibits growth-rate dependence for those
drugs targeting key cellular resources such as the ribosome, RNA polymerase, DNA gyrase,
18
and cell wall biosynthetic machinery. Our results show that for ribosome-targeting antibi-
otics, complex growth-rate dependent susceptibility can arise from the interplay between
molecular mechanism (antibiotic transport and binding) and cellular physiology (growth-
dependent constraints on ribosome concentration and synthesis rate). Interestingly, our
work shows that knowledge of the growth-rate dependence of the target (here, the ribo-
some) is not sufficient to predict the growth-rate dependence of the antibiotic susceptibility
– in fact, the nature of this dependence differs qualitatively among antibiotics despite their
common target (Fig. 1). Nonetheless, contrasting patterns of growth rate-dependent sus-
ceptibility can be explained quantitatively by combining mechanistic details of antibiotic
mode-of-action with empirically determined physiological constraints.
At higher concentrations than those considered here (∼ 10× IC50), other mechanisms
have been implicated in the inhibition of bacterial growth by ribosome-targeting antibiotics.
These include changes in the transmembrane proton-motive force, membrane permeabi-
lization by misfolded protein [14], induction of a heat-shock response [37], and, on longer
time scales, oxidative stress which increases mutation rate and accelerates the emergence
of resistance [38]. A complete picture of antibiotic action will require integration of
specific response mechanisms, such as these, with general constraints imposed by pathogen
growth, although the simple model presented here appears to capture the majority of the
growth-dependent susceptibility to the ribosome-targeting antibiotics tested. Applying a
similar approach to other classes of antibiotics or chemotherapeutic agents should provide
a clearer picture of in vivo drug action.
Clinical and evolutionary perspectives
From a clinical perspective, the strong positive correlation of the IC50 with drug-free growth
rate that we observe for our irreversibly-binding antibiotics suggests that the efficacy of
treatment could be improved by modulating the bacterial growth rate using a metabolic
inhibitor – echoing recent developments in understanding the role of nutrient environment
in overcoming persistent infections [8]. The threshold-like transition in the inhibition curve
for irreversibly-binding antibiotics can, however, greatly facilitate acquisition of resistance,
especially in the presence of steep spatial gradients of antibiotic [3, 5, 39], providing yet
another caution against their improvident use [40]. More broadly, it is becoming clear
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that understanding and manipulating pathogen physiology plays a major role in improving
strategies for the eradication of infection. Although both drug action and pathogen
metabolism are mechanistically complex, the interplay between molecular interactions and
whole-cell physiology can nevertheless be understood quantitatively using simple rules.
Methods
Antibiotics
Antibiotics were obtained from Fisher Scientific: Streptomycin sulfate (BP910-50),
Kanamycin Sulfate (BP906-5), Tetracycline hydrochloride (BP912-100) and Chlorampheni-
col (BP904-100). Stock solutions were prepared weekly, and stored at 4 ◦C. To avoid
degradation of the antibiotics (particularly tetracycline), cultures were grown no longer
than 6 hours before transfer to medium containing fresh antibiotic and all experiments were
performed in light-insulated shakers.
Growth media
The growth media is potassium morpholinopropane sulfonate (MOPS) buffered, and
is a modification of Neidhardt supplemented MOPS defined media [25] obtained from
Teknova (M2101). Carbon sources used were glycerol (0.2% v/v) and glucose (0.2% w/v).
Intermediate growth rates were obtained by supplementing glycerol and glucose minimal
media with casamino acids (0.2% w/v). The most rapid growth rates were obtained by
supplementing the media with nucleotides (Teknova, M2103) and all amino acids (Teknova,
M2104).
Strains and growth conditions
Escherichia coli K12 strain MG1655 was used in this study. Seed cultures were grown in
LB medium (Bio Basic), and used to inoculate pre-cultures in appropriate growth media
without antibiotics. After over-night growth, pre-cultures were diluted (500 − 1000×)
to fresh media and allowed to resume exponential growth for at least three generations
before being diluted into media containing antibiotics. Cells were adapted to exponential
growth in antibiotics and grown in adapted growth for four generations before growth rate
measurements were taken. Cells were grown in 3 mL of culture media at 37 ◦C in 20 mm test
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tubes, shaken in a water bath (MaxQ 7000, Thermo-Fisher) at 250 rpm. Growth rate was
monitored by measuring OD600 on a Biomate 3S spectrophotometer (Thermo-Fisher) over
time, with cell viability corroborated by plating. The translational mutant strain appearing
in Fig. 6 is a rpsL point mutation that confers pseudo-dependence on streptomycin [20, 32],
moved from strain GQ9 [20] (also known as CH349 or UK317 [32]) into our wild type
background via P1 transduction.
Protein and RNA extraction
Total protein was determined using a modified Lowry method (Sigma, TP0300) [41, 42],
with bovine serum albumin as a standard. RNA quantification was done via cold perchloric
acid precipitation [43].
Data fits
Estimates for the critical parameter combinations λ∗0 and IC
∗
50 were obtained by fitting the
experimental growth inhibition curves λ(aex) to the solution of the cubic equation, Eq. 7.
These fits were carried out using Powell’s method [44].
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Figure legends
Figure 1
Antibiotic susceptibility depends on nutrient quality for four ribosome-targeting antibiotics:
irreversibly-binding antibiotics streptomycin (A & B) and kanamycin (C & D), and
reversibly-binding antibiotics tetracycline (E & F) and chloramphenicol (G & H). The left
panels show the growth rate λ of E. coli MG1655 relative to the drug-free growth rate λ0,
as a function of the antibiotic concentration. Growth inhibition data are shown for media
with glycerol as the carbon source. The arrows indicate increasing drug-free growth rate λ0.
The right panels show the half-inhibition concentration IC50 as a function of the drug-free
growth rate λ0. Carbon sources are denoted by symbol: glucose (circles), glycerol (squares),
and error bars denote the standard deviation among repeated measurements (Tables S2 and
S3). Media are variants of Neidhardt’s MOPS buffered medium [25]; see Methods for details.
Figure 2
Schematic view of the model and its dynamics. A. The model is focused on three state
variables: the intracellular concentration of antibiotic a, the concentration ru of ribosomes
unbound by antibiotic and the concentration rb of antibiotic-bound ribosomes. Two
mechanisms drive the dynamics: 1. Transport across the cell membrane and 2. Binding of
ribosomes and antibiotic. B. Constraints arising from empirical relations between ribosome
content and growth rate. Scott et al. [20] measured total ribosome content as a function
of growth rate. When growth rate is varied by nutrient composition, in the absence of
antibiotics, ribosome content ru correlates positively with growth rate λ, increasing linearly
from a minimum concentration of inactive ribosomes rmin (solid line). When growth rate
is decreased by imposing translational inhibition, total ribosome content rtot = ru + rb
increases, reaching a maximum rmax as growth rate decreases to zero (dashed lines). Note
that Scott et al. measured ribosome mass fraction; here we translate these to concentrations
(see Supplementary Information, Fig. S1).
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Figure 3
Model fits to growth inhibition curve data. The parameters λ∗0 and IC
∗
50 are obtained by
numerical fitting of the solution of the cubic equation, Eq. 7, to our experimental growth
inhibition curves. Data sets for different drug-free growth rates (i.e. the different curves in
each panel) were fitted simultaneously with the same values of λ∗0 and IC
∗
50, but separate
fits were obtained for glycerol-based and glucose-based media. Here we show the resulting
fits for glycerol-based media (symbols as in Fig. 1. of the main text). The parameters
obtained by this procedure are: Streptomycin, glycerol: λ∗0 = 0.31h
−1, IC∗50 = 0.19µg/ml,
streptomycin, glucose: λ∗0 = 0.57h
−1, IC∗50 = 0.36µg/ml, kanamycin, glycerol: λ
∗
0 = 0.17h
−1,
IC∗50 = 0.05µg/ml, kanamycin, glucose: λ
∗
0 = 0.47h
−1, IC∗50 = 0.26µg/ml, tetracycline,
glycerol: λ∗0 = 5.2h
−1, IC∗50 = 0.23µM, tetracycline, glucose: λ
∗
0 = 6.3h
−1, IC∗50 = 0.36µM,
chloramphenicol, glycerol: λ∗0 = 1.8h
−1, IC∗50 = 2.5µM, chloramphenicol, glucose:
λ∗0 = 1.5h
−1, IC∗50 = 4.1µM. These values of λ
∗
0 and IC
∗
50 are compared to literature data in
Table S4. Similar results are obtained if we instead fit our data directly to the predicted
universal relation for IC50(λ0) (Eq. 10); see Supplementary Information and Fig. S3.
Figure 4
Universal growth-dependent susceptibility curve. Data from the right panels of Fig. 1 are
rescaled by λ∗0 and IC
∗
50, obtained by fitting our growth inhibition data (Fig. 3). The black
line shows the model prediction for the universal curve, Eq. 10.
Figure 5
Growth inhibition curves for our bactericidal and bacteriostatic drugs collapse onto
two qualitatively different limiting forms as predicted by the model. A: Data for the
bactericidal antibiotics streptomycin (closed symbols) and kanamycin (open symbols)
collapse onto λ/λ0 = (1/2)[1 +
√
1− aex/IC50] (black line). B: Data for the bacteriostatic
antibiotics tetracycline (closed symbols) and chloramphenicol (open symbols) collapse onto
λ/λ0 = 1/[1 + aex/IC50] (black line).
Figure 6
The translation mutant shows growth-dependent susceptibility to tetracycline in quantita-
tive agreement with the model predictions. A: The mutant shows a reduced translational
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capacity compared to the wildtype strain. Translational capacity is given as the inverse
slope of a plot of the RNA/protein ratio versus drug-free growth rate λ0 [20]. The data
for the mutant are from this study (dashed line); wildtype data are taken from Scott et al.
[20] (solid line). The ratio of slopes (WT/MUT) gives the ratio of translational capacity
κMUTt /κ
WT
t = 0.65 (Table S5). The colored symbols indicate different growth media, as
in Fig. 1. B: Growth-dependent susceptibility to tetracycline for the translation mutant.
The model predicts that for a reversible drug such as tetracycline, IC50 =IC
∗
50λ
∗
0/(2λ0), so
that ICWT50 /IC
MUT
50 = (κ
WT
t /κ
MUT
t ) × (λMUT0 /λWT0 ) = (1/0.65) × (λMUT0 /λWT0 ) (since both
λ∗0 and IC
∗
50 are proportional to
√
κt). The symbols show IC
WT
50 measured on all 6 growth
media, divided by the ICMUT,MIN50 measured on glucose minimal or glycerol minimal medium
as appropriate, and the drug-free growth rate of the wildtype λWT0 similarly rescaled with
respect to the drug-free growth rate of the mutant in the corresponding minimal medium
λMUT,MIN0 . The data collapse onto a straight line with gradient (1/0.65), as indicated by
the solid black line. It is important to note that the solid line is not a line-of-best-fit, but
rather comes from taking the ratio of the slopes in panel A.
Figure 7
Shift in the network topology in the irreversible and reversible limits. A. In the limit that
either transport or binding are irreversible (as is the case for streptomycin and kanamycin),
the system exhibits a ‘toggle-switch’ topology, leading to a steep inhibition curve (Eq. 11).
B. In the limit of fully-equilibrated transport and binding (as is the case for tetracycline
and chloramphenicol), the model predicts more gradual inhibition (Eq. 12).
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